第一项始终是图钉的来源。总体可信度是各份资料对上方所用开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半。
J&J's 10-Q for the quarter to 28 June 2026 targets "completion within 18 to 24 months after the initial announcement" of 14 October 2025 (mid-April to mid-October 2027), and CFO Joseph Wolk said in July that J&J "is on track for a mid-2027 separation" (Bloomberg); "mid-2027" is read as the middle of the year, 1 July 2027, which sits inside that window.
Quartz: Wolk "noted that a mid-2027 separation timeline remains intact"; J&J could spin the unit off rather than sell it (per the WSJ).[1]
Bloomberg, 11 September 2026: CFO Joseph Wolk said on the July earnings call that J&J "is on track for a mid-2027 separation", the newest company timing, read as 1 July 2027; also reports the Apollo talks.[1]
MedTech Dive, 30 June 2026: Christina Zamarro named DePuy Synthes CFO ahead of the separation; J&J reaffirmed in April the 18-to-24-month target and booked $119M of spinoff costs in Q1.
J&J's original announcement as filed with the SEC[1]: the Company "is targeting completion within 18 to 24 months", subject to works councils, board approval and regulatory approvals.
有遗漏或错误吗？用你自己的话说明：能佐证此图钉的链接、不同的开始或结束日期及理由，或缺失、有误的信息。AI 会对照此图钉的来源进行核实，搜索更好的来源，并添加任何支持你说法的页面。图钉自身的来源仍然最重要。
